Key risks
- Revenue declined 21% from ₹131.84 Cr (Sep 2025) to ₹103.31 Cr (Jun 2026); verify whether this reflects cyclical downturn or structural deterioration
- Net profit spiked to ₹88.14 Cr (Sep 2025) then settled to ₹40-50 Cr range in subsequent quarters; verify composition of Sep 2025 results—if exceptional gains, core business is significantly weaker than margins suggest
- Stock declined 26% over 12 months to ₹28.35 and trades near 52-week low (₹24.01); verify what drove repricing and whether fundamentals deteriorated
- Minimal institutional investor participation (FII 2.03%, DII 5.05%) despite PE 8.17; verify whether absence reflects business concerns or research gap
Generated analysis · source review pending